NAPOLI, CRISTINA
 Distribuzione geografica
Continente #
NA - Nord America 1.907
EU - Europa 1.765
AS - Asia 414
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.092
Nazione #
US - Stati Uniti d'America 1.900
PL - Polonia 630
RU - Federazione Russa 586
IE - Irlanda 171
SE - Svezia 135
HK - Hong Kong 119
SG - Singapore 104
CN - Cina 101
IT - Italia 95
DE - Germania 44
JO - Giordania 44
FI - Finlandia 29
IN - India 23
GB - Regno Unito 21
CH - Svizzera 14
VN - Vietnam 13
BE - Belgio 12
ES - Italia 11
AT - Austria 7
CA - Canada 7
TR - Turchia 7
CI - Costa d'Avorio 5
UA - Ucraina 4
DK - Danimarca 2
NL - Olanda 2
EU - Europa 1
ID - Indonesia 1
IR - Iran 1
KR - Corea 1
NO - Norvegia 1
PT - Portogallo 1
Totale 4.092
Città #
Warsaw 628
Santa Clara 397
Chandler 176
Dublin 171
Fairfield 163
Ashburn 125
Cambridge 95
Singapore 84
Ann Arbor 83
Seattle 82
Houston 78
Hong Kong 74
Woodbridge 72
Wilmington 59
Beijing 41
Princeton 35
Altamura 34
Bremen 31
Lawrence 31
Buffalo 29
Florence 29
Shanghai 27
Boston 21
Boardman 20
Kent 19
Medford 17
Mumbai 17
San Diego 17
New York 15
Bern 14
Barcelona 11
Brussels 11
Council Bluffs 9
Falls Church 7
Helsinki 7
Jacksonville 7
Moscow 7
Vienna 7
Dong Ket 6
Phoenix 6
West Jordan 6
Abidjan 5
Norwalk 5
Pune 5
Toronto 5
Redmond 4
Guangzhou 3
Hillsboro 3
Izmir 3
Lappeenranta 3
Latina 3
London 3
Washington 3
Copenhagen 2
Los Angeles 2
Munich 2
Philadelphia 2
Radomsko 2
Sesto Fiorentino 2
Shenzhen 2
Surrey 2
Andover 1
Aprilia 1
Arezzo 1
Atlanta 1
Baotou 1
Bologna 1
Central District 1
Hounslow 1
Kilburn 1
Kunming 1
Laurel 1
Lisbon 1
Lucca 1
Miami 1
Naaldwijk 1
Nanjing 1
New Bedfont 1
Newark 1
Oggiono 1
Paceco 1
Palermo 1
Redwood City 1
Rui'an 1
Seoul 1
Taiyuan 1
Tappahannock 1
Udine 1
Valdobbiadene 1
Wenzhou 1
Yubileyny 1
Zhengzhou 1
Totale 2.860
Nome #
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 278
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 247
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 237
Druggable Targets in Pancreatic Adenocarcinoma 230
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 187
Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies 172
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 139
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 138
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 135
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 119
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 115
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 112
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 107
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 100
Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616) 98
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 93
Pharmacological modulation of protein kinase C for overcoming drug resistance in colorectal cancer. Preliminary results of in vitro studies. 89
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 89
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 89
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers 87
Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma 87
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 84
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphysms in primary colorectal cancer patients. 80
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 80
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 73
In vitro activity of folate antagonists against methotrexate-resistant CCRF-CEM human T-leukemia sublines and relationships with folate pathway gene expression profiles 68
Thymidylate Synthase (TS) mRNA expression and TS gene promoter polymorphism in primary colorectal cancer (CRC) patients (PTS) receiving post-operative fluorouracil (5-FU)-based chemotherapy (CT) 68
Pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B cell lymphoma: preliminary results 66
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 64
Sequence-dependent interactions between oxaliplatin and 5-fluorouracil in human colon carcinoma cell lines 64
Expression of thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) genes by polymerase chain reaction (PCR) in gastric cancer patients (PTS): preliminary results 62
In vitro activity of folate antagonists against methotrexate-resistant CCRF-CEM human T-leukemia sublines and relationships with folate pathway gene expression profiles 58
Identification of pharmacogenomic markers of 5-fluorouracil-based chemotherapy in colorectal cancer 56
Marked variation thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) gene expression in human colorectal cancer 55
Comparative genomic hybridization study of genetic changes associated with 5-fluorouracil resistance in HCT-8 colon cancer cell lines: correlations with the expression profiles 55
Role of Non-Coding RNAs in Colorectal Cancer: Focus on Long Non-Coding RNAs 54
Quantitation of intratumoral thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) gene expression by the Polymerase Chain Reaction (PCR): marked variation among human colorectal cancer patients 47
Molecular analysis of the FHIT gene in human sporadic colon cancers. 45
The role of thymidylate synthase (TS) expression in prognosis and outcome of 5-fluorouracil (5-FU)-based chemotherapy in patients (pts) with colorectal cancer (CC) 45
Preliminary results of thymidylate synthase (TS) and folylpolyglutamate synthetase (FPGS) gene expression analysis by polymerase chain reaction (PCR) in gastric cancer patients (PTS) 43
Targeting z-Crystallin by aspirin restores the sensitivity to cisplatin in resistant A2780 ovarian cancer cells 37
Totale 4.152
Categoria #
all - tutte 11.458
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.458


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020457 0 0 0 0 74 64 72 72 60 46 61 8
2020/2021364 34 40 1 49 19 31 34 21 38 45 29 23
2021/2022242 6 22 11 13 7 16 6 26 15 12 39 69
2022/2023818 59 128 40 80 63 140 105 49 104 3 18 29
2023/2024335 7 26 43 10 18 48 30 88 6 15 33 11
2024/20251.259 68 189 132 365 505 0 0 0 0 0 0 0
Totale 4.152